China Universal Asset Management Co. Ltd. Has $330,000 Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

China Universal Asset Management Co. Ltd. lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 10.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,920 shares of the biotechnology company’s stock after buying an additional 4,129 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in BioCryst Pharmaceuticals were worth $330,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. R Squared Ltd acquired a new position in BioCryst Pharmaceuticals during the fourth quarter worth $48,000. KBC Group NV grew its holdings in shares of BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 4,537 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after purchasing an additional 375,890 shares in the last quarter. Exome Asset Management LLC bought a new position in BioCryst Pharmaceuticals during the 3rd quarter valued at about $1,493,000. Finally, Franklin Resources Inc. boosted its position in BioCryst Pharmaceuticals by 177.8% in the third quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company’s stock valued at $1,968,000 after buying an additional 168,790 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Up 0.4 %

Shares of NASDAQ:BCRX opened at $7.90 on Monday. The stock has a market capitalization of $1.64 billion, a P/E ratio of -12.95 and a beta of 1.76. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88. The business has a 50-day moving average price of $7.63 and a two-hundred day moving average price of $7.69.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. During the same quarter in the prior year, the company earned ($0.19) earnings per share. The company’s quarterly revenue was up 35.1% on a year-over-year basis. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Evercore ISI lifted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC boosted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Barclays raised their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, JMP Securities restated a “market outperform” rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $15.50.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.